6-isopropyl-4-hydroxy-pyrimidine | 124703-81-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 6-isopropyl-4-hydroxy-pyrimidine
• 英文别名: 4-hydroxy-6-isopropylpyrimidine；6-Isopropylpyrimidin-4-ol；4-propan-2-yl-1H-pyrimidin-6-one
• CAS: 124703-81-7
• 化学式: C₇H₁₀N₂O
• mdl: MFCD09909771
• 分子量: 138.169
• InChiKey: ZNWRDDRXQOKOLM-UHFFFAOYSA-N

物化性质

• 熔点：
  133.5-134.5 °C(Solv: acetone (67-64-1))
• 沸点：
  217.9±23.0 °C(Predicted)
• 密度：
  1.13±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.428
• 拓扑面积：
  41.5
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2933599090

反应信息

• 作为反应物：
  描述：

  6-isopropyl-4-hydroxy-pyrimidine 以 溶剂黄146 为溶剂， 生成 5-chloro-4-hydroxy-6-isopropylpyrimidine
  参考文献：
  名称：

  EP1333029

  摘要：

  公开号：
• 作为产物：
  描述：

  甲脒盐酸盐 、 异丁酰乙酸乙酯 在 硫酸 、 sodium methylate 作用下， 以 甲醇 为溶剂， 生成 6-isopropyl-4-hydroxy-pyrimidine
  参考文献：
  名称：

  EP1333029

  摘要：

  公开号：

文献信息

• SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS
  申请人：GLAXOSMITHKLINE LLC

  公开号：US20150152108A1

  公开（公告）日：2015-06-04

  The present invention relates to novel substituted bridged urea compounds, corresponding related analogs, pharmaceutical compositions and methods of use thereof. Sirtuin-modulating compounds of the present invention may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders, which include, but are not limited to, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. The present invention also related to compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.

  本发明涉及新型取代桥式脲化合物，相应的相关类似物，药物组合物以及其使用方法。本发明的抑制素调节化合物可用于延长细胞寿命，并治疗和/或预防各种疾病和疾病，包括但不限于与衰老或压力、糖尿病、肥胖、神经退行性疾病、心血管疾病、血液凝块疾病、炎症、癌症和/或潮红有关的疾病或疾病，以及那些会受益于增加线粒体活性的疾病或疾病。本发明还涉及包含抑制素调节化合物与另一治疗剂组合的组合物。
• NOVEL STING AGONISTS
  申请人：Venenum Biodesign, LLC

  公开号：US20200131209A1

  公开（公告）日：2020-04-30

  The present invention provides compounds of Formula I′: wherein , W, X, Y, Z, Z 1 , Z 2 , R 1 , R 2 , R 3 , R 4 and R 5 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are effective at modulating the STING protein and thus can be used as medicaments for treating or preventing disorders affected by the agonism of STING.

  本发明提供了式I′的化合物： 其中 , W, X, Y, Z, Z 1 , Z 2 , R 1 , R 2 , R 3 , R 4 和R 5 如本文所定义，或其立体异构体、互变异构体、药学上可接受的盐、前药酯或溶剂化合物形式，其中所有变量均如本文所定义。这些化合物能有效调节STING蛋白，因此可用作治疗或预防受STING激动影响的疾病的药物。
• Cathepsin cysteine protease inhibitors
  申请人：Gauthier Yves Jacques

  公开号：US20060111440A1

  公开（公告）日：2006-05-25

  This invention relates to a novel class of compounds which are cysteine protease inhibitors, including but not limited to, inhibitors of cathepsins K, L, S and B. These compounds are useful for treating diseases in which inhibition of bone resorption is indicated, such as osteoporosis.

  这项发明涉及一类新型化合物，它们是半胱氨酸蛋白酶抑制剂，包括但不限于对卡特普辛K、L、S和B的抑制剂。这些化合物可用于治疗需要抑制骨吸收的疾病，如骨质疏松症。
• Substituted isoquinoline-1,3(2H,4H)-diones, 1-thioxo-1,4-dihydro-2H-isoquinoline-3-ones and 1,4-dihydro-3 (2H)-isoquinolones and methods of use thereof
  申请人：Tsou Hwei-Ru

  公开号：US20080085890A1

  公开（公告）日：2008-04-10

  This invention provides compounds of Formula (I), having the structure where G 1 , G 2 , G 3 , G 4 , A 1 , A 2 , Y 1 , Y 2 , L 1 , Z, e and f are defined herein, or a pharmaceutically acceptable salt thereof, which are useful for treating or preventing cancer.

  这项发明提供了具有结构的化合物（I），其中G1、G2、G3、G4、A1、A2、Y1、Y2、L1、Z、e和f在此处定义，或其药用可接受盐，用于治疗或预防癌症。
• Process for preparing 4-hydroxypyrimidine
  申请人：UBE Industries, Ltd.

  公开号：US04935516A1

  公开（公告）日：1990-06-19

  A process for preparing a 4-hydroxypyrimidine of Formula III: ##STR1## wherein R.sub.1 and R.sub.2 each represent a hydrogen atom, an alkyl group having 1 to 10 carbon atoms, a cycloalkyl group having 3 to 10 carbon atoms or an aralkyl group having 2 to 10 carbon atoms, and R.sub.4 represents hydrogen an alkyl group having 1 to 10 carbon atoms, a cycloalkyl group having 3 to 10 carbon atoms, an aralkyl group having 7 to 10 carbon atoms or an aryl group having 6 to 10 carbon atoms, which comprises subjecting a 3-amino-2-unsaturated carboxylate of Formula I: ##STR2## wherein R.sub.1 and R.sub.2 are as defined above and R.sub.3 represents an alkyl group having 1 to 10 carbon atoms, a cycloalkyl group having 3 to 10 carbon atoms or an aralkyl group having 7 to 10 carbon atoms, and a carboxylic acid amide of Formula II: R.sub.4 CONH.sub.2 wherein R.sub.4 is as defined above, to reaction with each other in the presence of a base.

  一种制备化合物III的4-羟基嘧啶的方法：其中R₁和R₂分别表示氢原子，具有1至10个碳原子的烷基基团，具有3至10个碳原子的环烷基基团或具有2至10个碳原子的芳基基团，R₄表示氢原子，具有1至10个碳原子的烷基基团，具有3至10个碳原子的环烷基基团，具有7至10个碳原子的芳基基团或具有6至10个碳原子的芳基基团，包括将化合物I的3-氨基-2-不饱和羧酸酯：其中R₁和R₂如上定义，R₃表示具有1至10个碳原子的烷基基团，具有3至10个碳原子的环烷基基团或具有7至10个碳原子的芳基基团，以及化合物II的羧酰胺：R₄CONH₂其中R₄如上定义，在碱存在下使它们相互反应的方法。